share_log

白云山(00874)控股股东广药集团收到最高法院关于“王老吉”商标法律纠纷诉讼案件的重审阶段二审案件上诉受理通知书

Guangzhou Pharmaceutical Group, the controlling shareholder of Baiyunshan (00874), received the Supreme Court's notice of acceptance of the appeal in the second instance of the retrial phase of the “Wang Laoji” trademark legal dispute lawsuit

Zhitong Finance ·  11/15/2023 17:57

Baiyunshan (00874) announced that Guangzhou Pharmaceutical Group Co., Ltd., the controlling shareholder of the company (hereinafter referred to as “Guangzhou Pharmaceutical Group” or...

According to the Zhitong Finance App, Bai Yunshan (00874) announced that Guangzhou Pharmaceutical Group Co., Ltd. (hereinafter referred to as “Guangzhou Pharmaceutical Group” or the “Appellant”), the controlling shareholder of the company, received a notice of acceptance of the appeal from the Supreme People's Court of the People's Republic of China on November 14, 2023 in the retrial phase of the “Wang Laoji” trademark legal dispute lawsuit. The content relates to a civil lawsuit filed by Guangzhou Pharmaceutical Group, the controlling shareholder of the company, with the Guangdong Higher People's Court against Guangdong Gadobo Drinks and Food Co., Ltd., Zhejiang Gadobo Drinks Co., Ltd., Gadobo (China) Drinks Co., Ltd., Fujian Gadobo Drinks Co., Ltd., Hangzhou Gadobo Drinks Co., Ltd., and Wuhan Gadobo Drinks Co., Ltd. (the aforementioned six defendants are collectively referred to as “Liujiao Company”) to claim compensation for economic losses totaling 2,930 billion yuan for Guangzhou Pharmaceutical Group's economic losses due to infringement of Guangzhou Pharmaceutical Group's “Wang Laoji” registered trademark.

According to the announcement, the appellant, Guangzhou Pharmaceutical Group, filed an appeal with the Supreme Court in accordance with the law, and received the Supreme Court's appeal acceptance notice in the second instance of the “Wang Laoji” trademark legal dispute case. The appeal request for the case is as follows: revoke (2020) the first item of civil judgment No. 4 of Guangdong Minchu, and revise the judgment of Liujiadobao to jointly indemnify Guangzhou Pharmaceutical Group for economic losses of about 2.93 billion yuan; the litigation costs for the first and second trials in the retrial stage of this case were borne by Liujiadobo.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment